MicroRNA-28-5p Regulates Liver Cancer Stem Cell Expansion via IGF-1 Pathway

Figure 5

miR-28-5p knockdown HCC cells are more sensitive to sorafenib treatment. (a) The expression of miR-28-5p in sorafenib-resistant HCC xenografts was determined by RT-PCR assay (). (b) The expression of miR-28-5p in sorafenib-resistant HCC cells and control cells was determined by RT-PCR assay (). (c) The miR-29-5p mimic and control HCC cells were treated with sorafenib (10 μM) for 48 hours and subjected to flow cytometry assay (). (d) The miR-29-5p sponge and control HCC cells were treated with sorafenib (10 μM) for 48 hours and subjected to flow cytometry assay (). (e) The miR-29-5p mimic and control HCC cells were treated with sorafenib (10 μM) for 48 hours and subjected to western blot assay. GAPDH acted as a loading control. (f) The expression of miR-28-5p in PDX primary tumors was determined by RT-PCR assay. (g) PDXs with low or high miR-28-5p levels in their primary tumors were treated with sorafenib (60 mg/kg body weight) or vehicle for 30 days ( for each group). The terminal tumor size and weight was showed. Data are represented as ; ; two-tailed Student’s -test.

(a)

(b)

(c)

(d)

(e)

(f)

(g)